Standard BioTools

Standard BioTools FCF/Net Income

The Free Cash Flow to Net Income Ratio of Standard BioTools (LAB) as of Nov 5, 2026 is 110.36 %. In the previous year, Free Cash Flow to Net Income Ratio was 109.31 % — a change of 0.96% (higher).

FCF/Net Income

110.36 %

YoY

0.96%

Last updated:

Free Cash Flow to Net Income Ratio of Standard BioTools is 2025 110.36 % . Free Cash Flow to Net Income Ratio of Standard BioTools was 2024 109.31 % . It decreases by 0.96% higher compared to the previous year.

The Standard BioTools FCF/Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Net Income
Date
FCF/Net Income
Jan 1, 2018
43.33 USD
Jan 1, 2019
58.25 USD
Jan 1, 2020
53.06 USD
Jan 1, 2021
96.77 USD
Jan 1, 2022
49.02 USD
Jan 1, 2023
61.77 USD
Jan 1, 2024
109.31 USD
Jan 1, 2025
110.36 USD
The Standard BioTools FCF/Net Income history
YEARFCF/Net IncomeYoY
110.36 %+0.96%
109.31 %+76.94%
61.77 %+26.01%
49.02 %-49.34%
96.77 %+82.37%
53.06 %-8.91%
58.25 %+34.42%
43.33 %+2.02%
42.48 %-26.91%
58.12 %-31.67%
85.06 %+49.66%
56.84 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Standard BioTools Stock analysis

What does Standard BioTools do? Fluidigm Corp is a biotechnology company specializing in innovative devices and solutions for DNA sequencing. The company was founded in 1999 in San Francisco and is currently headquartered in South San Francisco. It developed the Microfluidic Technology-Sensor, which allows for handling tiny amounts of fluids in a small space. This technology has enabled researchers to analyze complex samples and collect data with high accuracy. The company operates in two main segments: Analytical Instruments and Sample Preparation. In the Analytical Instruments segment, Fluidigm offers various devices suitable for DNA sequencing, including the Juno, C1, and Biomark platforms. It also provides a wide range of consumables to facilitate sample preparation. The Sample Preparation segment offers products and services to prepare and process samples for analysis, including microfluidic technology chips and modules, single-cell sequencing systems, and products for next-generation sequencing. Fluidigm serves customers in various industries, such as genomics research, cancer research, and medical fields, with a strong presence in North America, Europe, and Asia. The company is known for its continuous investment in research and development, as well as its innovative technologies and patents. Overall, Fluidigm's Microfluidic technology platform allows researchers to collect data in a small space with high accuracy. With a diversified portfolio of products and services, the company is well-positioned to continue growing and expanding its market presence in the coming years. Standard BioTools is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Standard BioTools stock

Free Cash Flow to Net Income Ratio of Standard BioTools is 110.36 % in 2025.

Free Cash Flow to Net Income Ratio of Standard BioTools changed from 109.31 % to 110.36 %, representing a 0.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Net Income Ratio Standard BioTools since 2006 – with annual values, charts, and detailed analysis.

The FCF/Net Income ratio measures cash flow quality. Ratios consistently above 100% suggest high-quality earnings with strong cash backing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Net Income Ratio's Standard BioTools with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow to Net Income Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow to Net Income Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Standard BioTools

All Key Metrics — Standard BioTools